Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Socioeconomic aspects of incretin-based therapy
Incretin-based therapies, particularly glucagon-like peptide-1 receptor agonists (GLP-1
RAs), have demonstrated cardiovascular benefits in people with type 2 diabetes. However …
RAs), have demonstrated cardiovascular benefits in people with type 2 diabetes. However …
SGLT2 inhibitors–the new standard of Care for Cardiovascular, renal and metabolic protection in type 2 diabetes: a narrative review
S Seidu, V Alabraba, S Davies, P Newland-Jones… - Diabetes Therapy, 2024 - Springer
A substantial evidence base supports the use of sodium-glucose cotransporter-2 inhibitors
(SGLT2is) in the treatment of type 2 diabetes mellitus (T2DM). This class of medicines has …
(SGLT2is) in the treatment of type 2 diabetes mellitus (T2DM). This class of medicines has …
Cardiovascular safety in type 2 diabetes with sulfonylureas as second-line drugs: a nationwide population-based comparative safety study
H Wang, RLM Cordiner, Y Huang, L Donnelly… - Diabetes …, 2023 - diabetesjournals.org
OBJECTIVE To assess the real-world cardiovascular (CV) safety for sulfonylureas (SU), in
comparison with dipeptidyl peptidase 4 inhibitors (DPP4i) and thiazolidinediones (TZD) …
comparison with dipeptidyl peptidase 4 inhibitors (DPP4i) and thiazolidinediones (TZD) …
Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile
AJ Scheen - Expert Opinion on Drug Safety, 2024 - Taylor & Francis
Introduction Patients with type 2 diabetes (T2DM) are at high risk of atherosclerotic
cardiovascular disease (ASCVD) and cardiovascular death. Cardiovascular protection is a …
cardiovascular disease (ASCVD) and cardiovascular death. Cardiovascular protection is a …
Bridging the gap in cardiovascular care in diabetic patients: are cardioprotective antihyperglycemic agents underutilized?
AJ Scheen - Expert Review of Clinical Pharmacology, 2023 - Taylor & Francis
Introduction Atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF) are two
major complications of type 2 diabetes (T2DM). Cardiovascular protection is a key objective …
major complications of type 2 diabetes (T2DM). Cardiovascular protection is a key objective …
Lipid-lowering strategies for primary prevention of coronary heart disease in the UK: a cost-effectiveness analysis
Aim We aimed to assess the cost effectiveness of four different lipid-lowering strategies for
primary prevention of coronary heart disease initiated at ages 30, 40, 50, and 60 years from …
primary prevention of coronary heart disease initiated at ages 30, 40, 50, and 60 years from …
GLP-1 receptor agonists and SGLT2 inhibitors in type 2 diabetes: pleiotropic cardiometabolic effects and add-on value of a combined therapy
AJ Scheen - Drugs, 2024 - Springer
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2
inhibitors (SGLT2is) have proven efficacy and safety in randomized clinical trials and …
inhibitors (SGLT2is) have proven efficacy and safety in randomized clinical trials and …
Do SGLT2 inhibitors and GLP-1 receptor agonists modulate differently the risk of stroke? Discordance between randomised controlled trials and observational studies
AJ Scheen - Diabetes & Metabolism, 2023 - Elsevier
Stroke represents a major burden in patients with type 2 diabetes, yet this cerebrovascular
complication has been less carefully investigated than the risk of cardiovascular mortality …
complication has been less carefully investigated than the risk of cardiovascular mortality …
The current role of SGLT2 inhibitors in type 2 diabetes and beyond: a narrative review
AJ Scheen - Expert Review of Endocrinology & Metabolism, 2023 - Taylor & Francis
Introduction Sodium-glucose cotransporter 2 inhibitors (SGLT2is, gliflozins), the most recent
oral antihyperglycaemic agents, provide a cardiorenal protection, an effect independent of …
oral antihyperglycaemic agents, provide a cardiorenal protection, an effect independent of …
Utilization and cost of non‐insulin glucose‐lowering drugs in Australia from 2013 to 2023
Objectives To investigate the utilization and costs of non‐insulin glucose‐lowering drugs
(GLDs) in Australia from 2013 to 2023. Materials and Methods We conducted a retrospective …
(GLDs) in Australia from 2013 to 2023. Materials and Methods We conducted a retrospective …